TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients.
Tsakmaklis A, Farowski F, Zenner R, Lesker TR, Strowig T, Schlößer H, Lehmann J, von Bergwelt-Baildon M, Mauch C, Schlaak M, Knuever J, Schweinsberg V, Heinzerling LM, Vehreschild MJGT.
Tsakmaklis A, et al. Among authors: knuever j.
BMC Cancer. 2023 Nov 28;23(1):1160. doi: 10.1186/s12885-023-11551-5.
BMC Cancer. 2023.
PMID: 38017389
Free PMC article.